Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.

By C. Griffiths, B. Strober, P. C. van de Kerkhof, V. Ho, R. Fidelus-Gort, N. Yeilding, C. Guzzo, Yichuan Xia, Bei Zhou, Shu Li and 3 more. New England Journal of Medicine, 2010

866 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/88501bd6c08db514b3986e1cf12d676c7ce4193f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. C. Tato
2. D. Cua
3. R. Flavell
4. S. Gaffen

Citations in the corpus

• Innate IL-17-producing cells: the sentinels of the immune system (2010, background): “This is likely to have important consequences for therapeutic treatments as current clinical studies have shown efficacy for targeting IL-17 and IL-23 in human autoimmune disorder”
• Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab (2011, result): “The analyses did not detect a shift from a T H 1 to a T H 2 bias in the systemic immune system after ustekinumab treatment, which is further supported by the clinical data from the phase 3 clinical studies that showed no increase in asthma or allergic response”